Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News The inside story behind Samsung Bioepis’ European biosimilar takeover Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars. bySrinathJanuary 5, 2026